GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » PS Ratio

Alexion Pharmaceuticals (Alexion Pharmaceuticals) PS Ratio : 6.46 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Alexion Pharmaceuticals's share price is $182.50. Alexion Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $28.26. Hence, Alexion Pharmaceuticals's PS Ratio for today is 6.46.

Warning Sign:

Alexion Pharmaceuticals Inc stock PS Ratio (=6.41) is close to 2-year high of 6.58

The historical rank and industry rank for Alexion Pharmaceuticals's PS Ratio or its related term are showing as below:

ALXN' s PS Ratio Range Over the Past 10 Years
Min: 3.39   Med: 5.75   Max: 8.09
Current: 6.41

During the past 13 years, Alexion Pharmaceuticals's highest PS Ratio was 8.09. The lowest was 3.39. And the median was 5.75.

ALXN's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 8.92 vs ALXN: 6.41

Alexion Pharmaceuticals's Revenue per Sharefor the three months ended in Mar. 2021 was $7.35. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $28.26.

Good Sign:

Alexion Pharmaceuticals Inc has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Alexion Pharmaceuticals was 19.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 20.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 17.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 23.40% per year.

During the past 13 years, Alexion Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 462.40% per year. The lowest was -68.50% per year. And the median was 24.45% per year.

Back to Basics: PS Ratio


Alexion Pharmaceuticals PS Ratio Historical Data

The historical data trend for Alexion Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals PS Ratio Chart

Alexion Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.98 7.59 5.36 4.97 5.72

Alexion Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.77 4.50 4.29 5.72 5.43

Competitive Comparison of Alexion Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Alexion Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alexion Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Alexion Pharmaceuticals's PS Ratio falls into.



Alexion Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Alexion Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=182.50/28.264
=6.46

Alexion Pharmaceuticals's Share Price of today is $182.50.
Alexion Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $28.26.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Alexion Pharmaceuticals  (NAS:ALXN) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Alexion Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
121 Seaport Boulevard, Boston, MA, USA, 02210
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.
Executives
Daniel Bazarko officer: SVP, Controller, CAO C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino officer: EVP & CCAO C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law officer: EVP, Chief Experience Officer C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff officer: EVP & Chief Commercial Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff officer: EVP, Research & Development C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini officer: EVP, Chief Compliance Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen director 176 SOUTH STREET HOPKINTON MA 01748
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt director C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Headlines

From GuruFocus

Alexion Pharmaceuticals Stock Appears To Be Fairly Valued

By GF Value GF Value 04-04-2021

Alexion Shareholders Approve Acquisition by AstraZeneca

By Business Wire Business Wire 05-11-2021